血液和组织内HBVDNA定量检查的临床意义

Survey on the significance of HBVDNA quanlitative assay in blood and visceral tissues

HBV感染的治疗应以抗病毒为主 ,评价疗效应以HBVDNA消长来衡量。用PCR定量法不加选择地观察98例HBV急慢性感染病例的血液和肝、脾、肾、脑组织内HBVDNA含量。急性HBV感染血和肝组织内HBVDNA阳性率和平均含量均较低 ,慢性感染则均明显较高。治疗血内HBVDNA阴转后 ,肝组织内多数亦随之阴转。慢性HBV感染者血和肝、脾、肾、脑组织均可查见HBVDNA ,肝、脾脏组织内含量较高 ,少数阴转可能晚于血液 ,不应忽略巩固治疗 ,防止复发。

Anti-virus treatment has been cousidered as an important measure for HBV infection and guantitative assay of HBVDNA was needed for evaluating therapeutic effects. Blood, liver, spleen, kidney and brain tissues were arbitrarily collected from HBV infected patients for HBVDNA quantitative assay. The positive rate and mean concentration of HBVDNA in blood and liver tissue were comparatively low in acute hepatitis patients, but in chronic cases, both were obviously higher than that of acute cases. Most cases had hepatocell-conversion of HBVDNA at serocon-version of HBVDNA after treatment except a few cases with very low titer. The HBVDNA could be detected in blood. liver, spleen, kideny and brain tissues of chronic HBV infected cases and the positive rates and quantity of HBVDNA of visceral tissues were obviously higher than that of blood. So, consolidating treatment cauld not be neglected for the cases having had seroconversion of HBVDNA might come later owing to higher quantity for avoiding relapse.